HT
TEVA icon

Headlands Technologies’s Teva Pharmaceuticals TEVA Stock Holding History

Headlands Technologies’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-31,642
Closed -$486K – 1519
2025
Q1 		$486K Buy
31,642
+25,657
+429% +$458K 0.06% 293
2024
Q4 		$132K Buy
+5,985
New +$109K 0.01% 613
2024
Q3 		– Sell
-11,493
Closed -$187K – 1535
2024
Q2 		$187K Sell
11,493
-3,713
-24% -$57.2K 0.02% 493
2024
Q1 		$215K Buy
15,206
+11,745
+339% +$148K 0.05% 355
2023
Q4 		$36.1K Sell
3,461
-16,858
-83% -$157K 0.01% 581
2023
Q3 		$207K Sell
20,319
-6,803
-25% -$63.3K 0.1% 194
2023
Q2 		$204K Buy
+27,122
New +$220K 0.07% 277
2023
Q1 		– Sell
-274
Closed -$2K – 748
2022
Q4 		$2K Buy
+274
New +$2.39K ﹤0.01% 455

Other funds holding TEVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Headlands Technologies's TEVA Position: Q2 2025 in Review

Headlands Technologies sold out of Teva Pharmaceuticals (TEVA) in Q2 2025, closing a stake of 31,642 shares — an estimated $486K sold.

Headlands Technologies first reported a position in TEVA in Q4 2022 and held it in 8 quarters. The position peaked at $486K in Q1 2025. 539 funds tracked by Wall St. Rank hold TEVA as of Q2 2025.

  • Headlands Technologies reported no remaining Teva Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Headlands Technologies sold 31,642 Teva Pharmaceuticals shares in Q2 2025, an estimated $486K.
  • Headlands Technologies first reported a position in Teva Pharmaceuticals in Q4 2022 and held it in 8 quarters.
  • Headlands Technologies's Teva Pharmaceuticals position peaked at $486K in Q1 2025.
  • 539 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2025.

Based on Headlands Technologies's 13F filing for Q2 2025, filed 14 Aug 2025.